Table 3.

Clinical trials of Epstein Barr virus cytotoxic T lymphocytes in type II latency tumors

Patient number	Type of CTL	Antitumor l effects	Reference
Non-Hodgkin’s and Hodgkin’s Lymphoma
10	LCL-induced	2 CRs, 1 PR, 5 stable disease	Bollard et al. 2004 (50)
50	LMP-specific T cells using autologous dendritic cells and LCL transduced with an adenoviral vector expressing LMP2 or LMP1/2	Prophylaxis: 28 of 29 remain disease-free with median of 3 years follow up Treatment. 11 of 21 CRs, 2 PRs	Bollard et al. 2007(51) Bollard et al. 2013 (17)
3	LCL-induced from HLA-identical sibling (2) or autologous (1)	Stable disease for > 3 years in 2	Cho et al. 2006 (100)
Nasopharyngeal cancer
4	LCL-induced	Reduction in viral load but no clinical responses	Chua et al. 2001(101)
10	LCL-induced	2 PR and 4 with stable disease	Comoli et al. 2005 (6)
23	LCL-induced	Prophylaxis: 5 of 8 patients treated adjuvantly remained disease-free for 25 to 82 months and 3 relapsed. Treatment. 5 with CR, 2 with PR, 3 with Stable Disease, 5 with progression	Straathof et al. 2005 (53) Louis et al. 2010 (5)
8	LCL-induced after lymphodepletion with CD45	1 CR and 2 stable diseases	Louis et al. 2009 (54)
11	LCL-induced after cyclophosphamide and fludarabine	2 PRs, 3 with stable disease, 1 minor response	Secondino et al. (55)
35	LCL-induced after standard chemotherapy for metastatic disease	2-year overall survival OS was 67.2%	Teo et al. (30)

Abbreviations: LCL, lymphoblastoid cell line; LMP, latent membrane protein; CR, complete remission; PR, partial remission,